Target: ₹3,300
CMP: ₹2,547.15
Mankind Pharma’s vision to be an innovation-driven and differentiation-focused with high entry barrier products has found a match in Bharat Serums and Vaccines (BSV). We believe BSV has the potential to drive growth for longer periods and BSV’s Specialty strengths (R&D and sourcing as moats) would further Mankind’s vision.
Mankind’s strong India presence/network would spur a significant uptick in BSV’s India sales given huge complementarity/synergies. Specifically, IVF is an underpenetrated and a large market ($6 billion) and MNKI-BSV has the potential to become a global leader. We believe Street underappreciates the ‘Special’ty/biz moat of BSV both in the near and longer term.
Under Mankind’s capable management, we believe BSV could scale new heights and potentially generate a $1 billion sales/35 per cent+EBITDAM by FY32 (>1,000 bps improvement).
The company’s deep market presence and a track-record of creating brands have led to a consistent outperformance vs industry. Its scale-up in chronic against the odds is commendable and it has room to expand. Its 16k+ strong sales force is the backbone of its marketing muscle.
We forecast 18 per cent EBITDA CAGR (FY24-FY27E), value Mankind Pharma @ 30xSep’26 proforma EBITDA and initiate with a Buy.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.